How common are myeloproliferative neoplasms? A systematic review and meta-analysis-Reference-Cited by-同舟云学术

How common are myeloproliferative neoplasms? A systematic review and meta-analysis

Published:2014-03-11 Issue:6 Volume:89 Page:581-587
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Titmarsh Glen J.¹,Duncombe Andrew S.²,McMullin Mary Frances³,O'Rorke Michael¹,Mesa Ruben⁴,De Vocht Frank⁵,Horan Sarah⁶,Fritschi Lin⁷,Clarke Mike¹,Anderson Lesley A.¹

Affiliation:

1. Centre for Public Health; Queen's University Belfast; Belfast Northern Ireland

2. Department of Haematology; University Hospitals Southampton NHS Foundation Trust; Hampshire United Kingdom

3. Centre for Cancer Research and Cell Biology; Queen's University Belfast; Belfast Northern Ireland

4. Mayo Clinic Cancer Centre; Rochester Arizona

5. Centre for Occupational and Environmental Health; The University of Manchester; Manchester United Kingdom

6. School of Health Sciences; City University London; London United Kingdom

7. Western Australian Institute for Medical Research; The University of Western Australia; Perth Australia

Publisher

Wiley

Subject

Hematology

Reference78 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood,2009

2. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis;McMullin;Br J Haematol,2007

3. Guideline for investigation and management of adults and children presenting with a thrombocytosis;Harrison;Br J Haematol,2010

4. Guideline for the diagnosis and management of myelofibrosis;Reilly;Br J Haematol,2012

5. Bleeding and thrombosis in myeloproliferative disorders;Landolfi;Curr Opin Hematol,1998

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Splenectomy unveils thrombocytosis in underlying myeloproliferative neoplasms with extrahepatic portal vein obstruction;Intractable & Rare Diseases Research;2024-08-31

2. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial;International Journal of Hematology;2024-08-07

3. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Momelotinib: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-08

5. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM;Future Oncology;2024-07-29